Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Authors
Keywords
-
Journal
BMC INFECTIOUS DISEASES
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-31
DOI
10.1186/s12879-022-07068-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
- (2021) Hany M. Dabbous et al. ARCHIVES OF VIROLOGY
- Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial
- (2021) Iñigo Les Bujanda et al. Trials
- Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
- (2021) Ahmad Al-Abdouh et al. Contemporary Clinical Trials
- Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
- (2021) Masoud Solaymani-Dodaran et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
- (2021) Eduardo López-Medina et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Eugenia Abaleke et al. LANCET
- Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
- (2021) Christopher C Butler et al. LANCET
- Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients
- (2021) Nurullah Okumuş et al. BMC INFECTIOUS DISEASES
- Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial
- (2021) Raymond Chee Seong Seet et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
- (2021) Reaz Mahmud et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
- (2021) Hany M. Dabbous et al. Scientific Reports
- Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial
- (2021) Ilad Alavi Darazam et al. Scientific Reports
- Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
- (2021) Mohammad Bosaeed et al. BMJ Open
- The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
- (2021) Matthew J. Page et al. PLOS MEDICINE
- Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19
- (2021) Gilmar Reis et al. JAMA Network Open
- Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19
- (2021) Andreas Barratt-Due et al. ANNALS OF INTERNAL MEDICINE
- Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis
- (2021) George N. Okoli et al. Expert Review of Anti-Infective Therapy
- Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study
- (2021) Mahmoud El-Bendary et al. Expert Review of Anti-Infective Therapy
- Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
- (2021) Yaseen M. Arabi et al. INTENSIVE CARE MEDICINE
- Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
- (2021) Hong Zhao et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial
- (2021) Babak Sayad et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID‐19: A randomized controlled trial
- (2021) Sherif Abbass et al. JOURNAL OF MEDICAL VIROLOGY
- Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials
- (2021) Chih-Cheng Lai et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
- (2021) Tejas K. Patel et al. Journal of Infection and Public Health
- Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection
- (2021) Salil Gupta et al. Medical Journal Armed Forces India
- An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
- (2021) Florence Ader et al. CLINICAL MICROBIOLOGY AND INFECTION
- Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
- (2021) Ilad Alavi Darazam et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment
- (2020) Hossein Poustchi et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
- (2020) Kimiyasu Shiraki et al. PHARMACOLOGY & THERAPEUTICS
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
- (2020) Timothy P. Sheahan et al. Nature Communications
- Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
- (2020) Naveen Vankadari INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis
- (2020) Wei Liu et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial
- (2020) Fang Zheng et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
- (2020) Minchen Chien et al. JOURNAL OF PROTEOME RESEARCH
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)—protocol of randomised controlled trial AZIQUINE-ICU
- (2020) František Duška et al. Trials
- Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
- (2020) Luis F. García Frontiers in Immunology
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
- (2020) Hong Zhao et al. BIOMEDICINE & PHARMACOTHERAPY
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial
- (2020) Ehsan Sekhavati et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
- (2020) Anahita Sadeghi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
- (2020) Hamideh Abbaspour Kasgari et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2020) Peter W Horby et al. LANCET
- Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
- (2020) Remo H M Furtado et al. LANCET
- Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Development of a hemoptysis risk prediction model for patients following CT-guided transthoracic lung biopsy
- (2020) Saibin Wang et al. BMC Pulmonary Medicine
- Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
- (2020) Benjamin S. Abella et al. JAMA Internal Medicine
- Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
- (2020) Marzieh Nojomi et al. BMC INFECTIOUS DISEASES
- Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review
- (2020) Betsy Ann Joseph et al. Expert Review of Anti-Infective Therapy
- Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
- (2020) Faryal Khamis et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial
- (2020) Fatemeh Roozbeh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
- (2020) Sabeena Ahmed et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- SD1000: High Sustained Viral Response Rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost fixed-dose combination tablet of generic sofosbuvir and daclatasvir - a multicenter phase 3 clinical trial
- (2019) Shahin Merat et al. CLINICAL INFECTIOUS DISEASES
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Ebola virus dynamics in mice treated with favipiravir
- (2015) Vincent Madelain et al. ANTIVIRAL RESEARCH
- Clinical efficacy of Аrbidol (umifenovir) in the therapy of influenza in adults: Preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR
- (2015) O. I. Kiselev et al. TERAPEVTICHESKII ARKHIV
- Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
- (2014) Nikolaos Spanakis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol
- (2008) Irina A. Leneva et al. ANTIVIRAL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now